Evidence map›Paper›PMID 32171869›Full record

ArticleThe Journal of infection2020

Clinical progression of patients with COVID-19 in Shanghai, China.

Jun Chen, Tangkai Qi, Li Liu, Yun Ling, Zhiping Qian, Tao Li, Feng Li, Qingnian Xu, Yuyi Zhang, Shuibao Xu and 6 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of infection, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 433 papers, 15 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
433citing papers in PubMed, 15 pooled it
20.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

433 citing papers in PubMed, 15 syntheses or guidelines pooled it, 854 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Auxiliary Screening COVID-19 by Serology.Frontiers in public health · 2022
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Article

373 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 1 institution in 1 country.

Jun ChenDepartment of Infectious Diseases and Immunology, Shanghai Public Health Clinical Center, Shanghai 201508, China.
Tangkai QiDepartment of Infectious Diseases and Immunology, Shanghai Public Health Clinical Center, Shanghai 201508, China.
Li LiuDepartment of Infectious Diseases and Immunology, Shanghai Public Health Clinical Center, Shanghai 201508, China.
Yun LingDepartment of Infectious Diseases, Shanghai Public Health Clinical Center, 2901 Caolang Road, Shanghai 201508, China.
Zhiping QianDepartment of Liver Intensive Care Unit, Shanghai Public Health Clinical Center, Shanghai 201508, China.
Tao LiDepartment of Tuberculosis, Shanghai Public Health Clinical Center, Shanghai 201508, China.
Feng LiDepartment of Respiratory Diseases, Shanghai Public Health Clinical Center, Shanghai 201508, China.
Qingnian XuDepartment of Traditional Chinese Medicine, Shanghai Public Health Clinical Center, Shanghai 201508, China.
Yuyi ZhangDepartment of Liver Intensive Care Unit, Shanghai Public Health Clinical Center, Shanghai 201508, China.
Shuibao XuDepartment of Infectious Diseases and Immunology, Shanghai Public Health Clinical Center, Shanghai 201508, China.
Zhigang SongDepartment of Pathogen Diagnosis and Biosafety, Shanghai Public Health Clinical Center, Shanghai 201508, China.
Yigang ZengDepartment of Urology, Shanghai Public Health Clinical Center, 2901 Caolang Road, Shanghai 201508, China.
Yinzhong ShenDepartment of Infectious Diseases and Immunology, Shanghai Public Health Clinical Center, Shanghai 201508, China.
Yuxin ShiDepartment of Radiology, Shanghai Public Health Clinical Center, Shanghai 201508, China.
Tongyu ZhuDepartment of Urology, Shanghai Public Health Clinical Center, 2901 Caolang Road, Shanghai 201508, China. Electronic address: zhutongyu@shphc.org.cn.
Hongzhou LuDepartment of Infectious Diseases, Shanghai Public Health Clinical Center, 2901 Caolang Road, Shanghai 201508, China. Electronic address: luhongzhou@fudan.edu.cn.
Shanghai Public Health Clinical Center · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundStudies on the 2019 novel coronavirus disease (COVID-19) have generally been limited to the description of the epidemiology and initial clinical characteristics. We investigated the temporal progression in patients with COVID-19.

methodsIn this retrospective, single-center study, we included confirmed cases of COVID-19 from Jan 20 to Feb 6, 2020 in Shanghai. Final date of follow-up was February 25, 2020.

resultsOf the 249 patients enrolled, the median age was 51 years old, and 126 (50.6%) were male. The duration from onset of symptoms to hospitalization was 4(2-7) days in symptomatic patients. Fever was occurred in 235(94.3%) patients. A total of 215 (86.3%) patients had been discharged after 16(12-20) days hospitalization. The estimated median duration of fever in all the patients with fever was 10 days (95 confidential intervals [CIs]: 8-11 days) after onset of symptoms. Patients who were transferred to intensive care units (ICU) had significantly longer duration of fever as compared to those not in ICU (31 days v.s. 9 days after onset of symptoms, respectively, P <0.0001). Radiological aggravation of initial image was observed in 163 (65.7%) patients on day 7 after onset of symptoms. 154(94.5%) of these patients showed radiological improvement on day 14. The median duration to negative reverse-transcriptase PCR tests of upper respiratory tract samples was 11 days (95 CIs: 10-12 days). Viral clearance was more likely to be delayed in patients in ICU than those not in ICU (P <0.0001). In multivariate logistical analysis, age (Odds ratio [OR] = 1.06) and CD4 T cell count (OR = 0.55 per 100 cells/ul increase) were independently associated with ICU admission.

conclusionsThe majority of COVID-19 cases are mild. The clinical progression pattern suggests that early control of viral replication and application of host-directed therapy in later stage is essential to improve the prognosis of CVOID-19.

Indexed as

Disease ProgressionAdultBetacoronavirusChinaCoronavirus InfectionsCOVID-19FemaleFeverHospitalizationHumansMaleMiddle AgedPandemicsPneumonia, ViralPrognosisRetrospective StudiesClinical characteristicsClinical progressionCOVID-19SARS-CoV-2Viral clearance

Identifiers

PMID32171869
PMCPMC7102530
OpenAlexW3009155534

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.